|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300073111 |
|
最近更新日期: Date of Last Refreshed on: |
2023-07-01 22:08:09 |
|
注册时间: Date of Registration: |
2023-07-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
微波消融术对子宫腺肌病患者子宫内膜容受性及卵巢功能的影响分析 |
|
Public title: |
Effect of microwave ablation on endometrium receptivity and ovarian function in patients with adenomyosis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
微波消融术对子宫腺肌病患者子宫内膜容受性及卵巢功能的影响分析 |
|
Scientific title: |
Effect of microwave ablation on endometrium receptivity and ovarian function in patients with adenomyosis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李水平 |
研究负责人: |
李水平 |
|
Applicant: |
Shuiping Li |
Study leader: |
Shuiping Li |
|
申请注册联系人电话: Applicant telephone: |
+86 133 1399 0865 |
研究负责人电话:
Study leader's |
+86 133 1399 0865 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
49899530@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
49899530@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省龙岩市新罗区九一北路105号 |
研究负责人通讯地址: |
福建省龙岩市新罗区九一北路105号 |
|
Applicant address: |
NO.105,JiuYi North Road,IXinluo District,Longyan City, Fujian Province |
Study leader's address: |
NO.105,JiuYi North Road,IXinluo District,Longyan City, Fujian Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
福建医科大学附属龙岩市第一医院 |
||
|
Applicant's institution: |
The Longyan First Affiliated Hospital of Fujian Medical University |
||
|
研究负责人所在单位: |
福建医科大学附属龙岩市第一医院 |
||
|
Affiliation of the Leader: |
The Longyan First Affiliated Hospital of Fujian Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LYREC2023-k045-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
福建医科大学附属龙岩第一医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Ethic Committee of The Longyan First Affiliated Hospital of Fujian Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-06-27 00:00:00 | ||
|
伦理委员会联系人: |
王蕾 |
||
|
Contact Name of the ethic committee: |
Lei Wang |
||
|
伦理委员会联系地址: |
福建省龙岩市九一北路105号 |
||
|
Contact Address of the ethic committee: |
105 Jiuyibei Road,Longyan,Fujian,China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 136 0956 5462 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
福建医科大学附属龙岩第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Longyan First Affiliated Hospital of Fujian Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省龙岩市九一北路105号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
105 Jiuyibei Road,Longyan,Fujian,China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
龙岩市科技局 |
||||||||||||||||||||||
|
Source(s) of funding: |
Longyan Science and Technology Bureau |
||||||||||||||||||||||
|
研究疾病: |
子宫腺肌病 |
||||||||||||||||||||||
|
Target disease: |
Adenomyosis of the uterus |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本研究旨在通过观察子宫腺肌病患者经微波消融治疗前后子宫内膜容受性及卵巢功能相关指标的变化,探讨微波消融对其的影响,并采用单因素及多因素Logistic回归分析妊娠结局的影响因素,以期为临床此类患者的治疗提供数据参考,优化治疗策略. |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this study was to investigate the influence of microwave ablation on endometrium receptivity and ovarian function indexes of adenomyosis patients before and after microwave ablation, and to analyze the influencing factors of pregnancy outcome by univariate and multivariate Logistic regression, in order to provide data reference for the clinical treatment of these patients and optimize the treatment strategy. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.经超声及MRI检查诊断为AM;2.伴有AM相关症状,如痛经、月经量过多、经期延长等;3.有安全的经腹壁穿刺路径;4.希望保留子宫,拒绝药物或其他疗法,自愿接受MWA治疗. |
||||||||||||||||||||||
|
Inclusion criteria |
1. AM was diagnosed by ultrasound and MRI. 2. Accompanied by AM related symptoms, such as dysmenorrhea, excessive menstruation, prolonged menstruation, etc.; 3. There is a safe puncture path through the abdominal wall; 4. Wish to retain the uterus, refuse medication or other therapies, and voluntarily undergo MWA treatment. |
||||||||||||||||||||||
|
排除标准: |
1.妊娠期或哺乳期;2.子宫颈上皮内瘤变III级以上或伴有子宫内膜重度不典型增生;3.未控制的急、慢性盆腔及严重出血;4.严重的心、肺、肝等重要脏器功能障碍者;5.严重促凝血功能障碍. |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Pregnancy or lactation; 2. Cervical intraepithelial neoplasia above grade III or accompanied by severe endometrial dysplasia; 3. Uncontrolled acute, chronic and severe pelvic bleeding; 4. Severe dysfunction of heart, lung, liver and other important organs; 5. Severe procoagulant dysfunction. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-07-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-07-01 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成,论文发表时公开原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data is published when the paper is published |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |